TLR9 and lung cancer: NSCLC patients without metastasis have lower mitochondrial DNA (mtDNA) and lower TLR9 expression compared to those with metastasis; therefore, TLR9 and mtDNA can serve as potential biomarkers for lung cancer progression and metastasis (67).